Zivo Bioscience, Inc. (ZIVO): Nasdaq/NYSE listing notice — Zivo Bioscience receives Nasdaq delisting notice for insufficient equity

Zivo Bioscience, Inc.

Nasdaq notified Zivo on Nov 22, 2022 of non-compliance with minimum $2.5M stockholders' equity requirement.
Equity fell below threshold as of Sept 30, 2022; alternative compliance standards also not met.
Company has 45 days (until Jan 6, 2023) to submit a plan to regain compliance; possible 180-day extension.
No immediate impact on trading; common stock (ZIVO) and warrants (ZIVOW) continue trading on Nasdaq.

item 3.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

Zivo Bioscience, Inc. received a nasdaq deficiency notice notice regarding stockholders equity (rules 5550(b)(1)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: stockholders equity
Rules: 5550(b)(1)

Exact text from the filing

November 22, 2022, Zivo Bioscience, Inc. (the “Company”) received written notice from the Nasdaq Stock Market (“ Nasdaq ”) stating that the Company no longer complies with the minimum stockholders’ equity requirement under Nasdaq Listing Rule 5550(b)(1) for continued listing on The Nasdaq Capital Market because the Company’s stockholders' equity, as reported in the Company’s Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2022, has fallen below $2.5 million. The notice also indicates that the Company does not meet the alternative compliance standards. Under applicabl

View on SEC.gov

Browse all listing & compliance notices →

Zivo Bioscience, Inc. filing history →

Source: SEC EDGAR

accession 0001654954-22-015844

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.